Emergent BioSolutions Q3 revenues down 27% to $240M; net loss widens to $75.7M; guidance slashed

Emergent BioSolutions Inc.

2022-Q3 EPS reported -$2.71 revenue$790,200,000

Total revenues $240M (-27% YoY); net loss $75.7M (-$1.52 EPS) vs loss $32.7M (-$0.61) prior year.
Segment: Products revenue $186.2M (-31%); Services CDMO $36.4M (-13%); nasal naloxone -34%, ACAM2000 -39%, anthrax vaccines +55%.
Completed TEMBEXA acquisition from Chimerix; BARDA contract up to $680M for 1.7M doses over 10 years.
FY2022 guidance revised down: total rev $1.05-1.1B (from $1.15-1.25B); adj EBITDA $0-30M (from $80-120M); ACAM2000 cut to $63M.
Gross margin improved to 33% from 30%; adjusted gross margin 34% from 31%; attributed to mix shift.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Emergent BioSolutions Inc. reported the third quarter ended September 30, 2022 results: revenue Total Revenues $240.0, net income Net Loss $(75.7), EPS Net Loss per Diluted Share $(1.52).

Period: the third quarter ended September 30, 2022
Revenue: Total Revenues $240.0
Net income: Net Loss $(75.7)
EPS: Net Loss per Diluted Share $(1.52)
Result: reported results

Exact text from the filing

to deliver results for our patients, customers, and shareholders.” FINANCIAL HIGHLIGHTS (1) ($ in millions, except per share amounts) Q3 2022 Q3 2021 % Change Total Revenues $240.0 $329.0 (27)% Net Loss $(75.7) $(32.7) * Net Loss per Diluted Share $(1.52) $(0.61) * Adjusted Net Loss (2) $(63.2) $(19.3) * Adjusted Net Loss (2) per Diluted Share $(1.27)

View on SEC.gov

Browse all earnings releases →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR

accession 0001367644-22-000141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.